You are here:Home-Inhibitors & Agonists-Autophagy

Request The Product List ofAutophagy Autophagy

Cat. No. Product Name CAS No. Information



Aumitin is a novel potent autophagy inhibitor with IC50 of 124 and 244 nM against starvation- and rapamycin- induced autophagy respectively, targets mitochondrial complex I; inhibits LC3 lipidation, and p62 degradation by starvation- as well as rapamycin-induced autophagy dose-dependently in MCF7-LC3 cells, suggesting inhibition of autophagic flux; inhibits mitochondrial respiration by targeting complex I with IC50 of 0.11 uM in HeLa cells; Aumitin is a new tool compound for interrogating autophagy and mitochondrial respiration by means of complex I inhibition.



XRK3F2 is a specific ZZ-domain of ubiquitin-binding protein p62 (Sequestosome 1) inhibitor that inhibits MM cell growth and BMSC growth enhancement of human MM cells; inhibits TNFα-induced osteoclast formation, and has IC50 of 4.35 uM 5TGM1 cells and 4.6 uM for the human MM1.S cell line; induces new cortical bone formation in MMBD in vivo, and alters MM cell-BMSC cell interactions by reducing MM cell-derived TNFα in the myeloma microenvironment.




Lys05 (Lys01 trihydrochloride, PS-1001) is the water-soluble salt of Lys01, is a 10-fold more potent lysosomal autophagy inhibitor than hydroxychloroquine (HCQ); shows IC50 values of 3.6, 3.8, 6 and 7.9 uM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay; more potently accumulates within and deacidifies the lysosome, resulting in impaired autophagy and tumor growth; enhances sunitinib-mediated suppression of clear cell ovarian carcinoma (CCOC) cell viability.




ROC-325 (ROC 325, ROC325) is a novel, orally available inhibitor of lysosomal-mediated autophagy; exhibits superior in vitro anticancer effects compared with the existing autophagy inhibitor hydroxychloroquine (HCQ) in different cancer cell lines, including accumulation of autophagosomes with undegraded cargo, lysosomal deacidification, p62 stabilization, and disruption of autophagic flux; antagonizes RCC growth and survival in an ATG5/7-dependent manner, induces apoptosis and exhibited favorable selectivity; significantly more effective at inhibiting tumor progression than HCQ, and inhibited autophagy in vivo.




STF-62247 is a small molecule Autophagy inducer that induces autophagy and selectively induces lethality in VHL-deficient RCC cells; induces cytotoxicity and reduces tumor growth in VHL-deficient cells in a HIF-independent manner, PI3K and Golgi trafficking are required as initial signals in STF-62247-induced autophagy.

Kidney Cancer




851677-06-0 ABTL0812 (ABTL-0812) is a first-in-class 2-hydroxylinoleic acid that shows anticancer activity in vitro and in vivo, reduces viability of different human cancer cell lines with IC50 values of 20 to 60 uM; ABTL0812 induced death in cancer cells but not in normal cells; induced an upregulation of TRIB3 expression, resulting in the PI3K/AKT/mTOR axis inhibition and autophagy cell death induction on EC cells but not in healthy endometrial cells; ABTL0812 treatment also impaired PTEN knock-out cells to progress from hyperplasia to cancer.duces autophagy-mediated cell death, increases in LC3-II levels in tumors from A549 xenograft mice.

Pancreatic Cancer

Phase 1 Clinical



SLLN-15 (Autophagy inducer SLLN-15) is a potent, orally available inducer of autophagy that selectively activated cytostatic macroautophagy/autophagy in TNBC preclinical models, promotes AURKA degradation and ; induced a dose-dependent anti-proliferative activity in the TNBC cell lines MDA-MB-231 and BT-20 via induction of autophagy and autophagic flux, associated with a selective inhibition of AKT-MTOR signaling; SLLN-15-induced autophagy in TNBC cells was also associated with decreased AURKA expression decreased AKT phosphorylation and subsequent blockage of the AKT-MTOR pathway; demonstrates anticancer and anti-metastatic activity in mice bearing TNBC.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us